• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

The VITAL trial: Omega-3 supplementation does not reduce risk of cardiovascular events

byDayton McMillan
January 5, 2019
in Cardiology, Chronic Disease, Endocrinology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Healthy adult patients randomized to receive marine n-3 fatty acids (omega-3) experienced similar rates of adverse cardiovascular events as those receiving a placebo after 5 years of treatment.

2. Risk of death from any cause was similar for patients in the omega-3 and placebo groups.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Studies with varied endpoints have suggested omega-3 fatty acids may be beneficial for primary prevention of cardiovascular disease. Many of these studies are in selected or otherwise non-generalizable populations, thus making them difficult to apply to patients without cardiovascular risk factors. The Vitamin D and Omega-3 Trial (VITAL) was conducted to evaluate how omega-3 supplements may affect healthy patient’s risk for cardiovascular events or cancer. After a median follow-up of 5.3 years, patients randomized to the omega-3 group experienced similar risks of a major cardiovascular event as patients in the placebo group. Additionally, risk of either cancer diagnosis or death was not significantly different between groups randomized to omega-3 supplements or placebo.

This study was conducted in a large, healthy adult population making its results more generalizable than most prior studies. Strengths include the number of patients included, the randomized factorial design evaluating both omega-3 and vitamin D supplementation, and the extensive subgroup analysis. Limitations include study of a single dose of omega-3 supplementation and no statistical control for multiple hypothesis testing.

Click to read the study in NEJM

Relevant Reading: Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance

RELATED REPORTS

Vitamin D supplementation does not improve mental outcomes in adults with early psychosis

Wellness Check: Nutrition

Vitamin D supplementation not supported to treat first-episode psychosis

In-Depth [randomized controlled trial]: This randomized, placebo controlled trial enrolled healthy mature adult patients (men over 50, women over 55) between 2011 and 2014. Patients were factorially randomized to receive supplementation with a standardized dose of vitamin D (2000 IU per day), omega-3 fatty acid (840 mg per day, n=12933; n=12938 for patients receiving omega-3 placebo), both, or neither. Results of the study on outcomes associated with vitamin D supplementation are reported elsewhere. The primary endpoint of the study was a cardiovascular composite of myocardial infarction, stroke, or cardiovascular death. After a median of 5.3 years follow-up, this composite outcome occurred for 386 and 419 patients in the omega-3 and placebo groups, respectively (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24). Of the secondary cardiovascular outcomes assessed, only the hazard ratio for myocardial infarction risk favored patients in the omega-3 group (0.72; 95% CI, 0.59 to 0.90), with 95% CIs of hazard ratios for death from cardiovascular causes, stroke, and expanded composite of cardiovascular events all crossing 1. Invasive cancer was diagnosed in 820 and 797 patients in the omega-3 and placebo groups, respectively (HR, 1.03; 95% CI, 0.93 to 1.13; P=0.56). Incidence curves for cancer diagnosis of all types appeared similar throughout follow-up. When analysis was performed in multiple subgroups there was no subgroup found to significantly benefit from omega-3 supplementation with regards to the composite cardiovascular risk outcome. There was no difference in serious adverse events or gastrointestinal symptoms between the placebo and omega-3 groups.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: omega-3 fatty acidsvitamin d
Previous Post

#VisualAbstract: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Next Post

Meningococcus B rates higher among college students compared with noncollege peers

RelatedReports

Multiple opioid prescriptions associated with higher hospital admissions
Psychiatry

Vitamin D supplementation does not improve mental outcomes in adults with early psychosis

February 22, 2022
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

February 17, 2022
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Chronic Disease

Vitamin D supplementation not supported to treat first-episode psychosis

February 22, 2022
Higher omega-3 blood levels associated with larger brain volumes
Chronic Disease

Omega-3 fatty acid supplements did not reduce depression risk in adults compared to placebo

May 13, 2022
Next Post
Medical vaccine exemptions increase after elimination of nonmedical exemptions

Meningococcus B rates higher among college students compared with noncollege peers

#VisualAbstract: Mupirocin for Staphylococcus aureus Decolonization of Infants in Neonatal Intensive Care Units

#VisualAbstract: Mupirocin for Staphylococcus aureus Decolonization of Infants in Neonatal Intensive Care Units

Strict tobacco licensing laws linked to reduced adolescent smoking initiation

Strict tobacco licensing laws linked to reduced adolescent smoking initiation

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.